WTH Is Strategic Commissioning, Anyway? - Registration

Most pharma teams are still building their commissioning strategy for an NHS that no longer exists.

As commissioning shifts to ICBs, the way formulary, pathway and investment decisions are made is changing. Clinical evidence alone is no longer enough, with value and affordability increasingly shaping adoption.

On 8 October, Kandarp Thakkar and Minesh Parbat will break down what’s changing, what it means for industry, and what pharma teams need to do differently.

Ask the panel anything about access, commissioning or what’s next for the NHS medicines system, either in advance or live.

Complete your details below to register your place. A Microsoft Teams invitation will follow.

Question Title

1. First name: (Required.)

Question Title

2. Last name: (Required.)

Question Title

3. Job title: (Required.)

Question Title

4. Email address: (Required.)

Question Title

5. Organisation or workplace name: (Required.)

Question Title

6. If you have any questions for our Q&A, please share here.

WTH Is Strategic Commissioning, Anyway? - Registration

Question Title

* 1. First name: (Required.)

Question Title

* 2. Last name: (Required.)

Question Title

* 3. Job title: (Required.)

Question Title

* 4. Email address: (Required.)

Question Title

* 5. Organisation or workplace name: (Required.)

Question Title

* 6. If you have any questions for our Q&A, please share here.

1. First name: (Required.)

2. Last name: (Required.)

3. Job title: (Required.)

4. Email address: (Required.)

5. Organisation or workplace name: (Required.)

6. If you have any questions for our Q&A, please share here.